NWBO (Northwest Biotherapeutics) Institutional Ownership: 0.02% (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NWBO Northwest Biotherapeutics Inc NWBO
11 GF Score
Price $0.17
! 5 Warning Signs
View Full Analysis

What is Northwest Biotherapeutics Institutional Ownership?

Northwest Biotherapeutics NWBO -3.62% 11 Institutional Ownership is 0.02% as of Jul. 21, 2026. GuruFocus rates NWBO with a GF Score™ of 11/100. The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Northwest Biotherapeutics's institutional ownership is 0.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Northwest Biotherapeutics's Insider Ownership is 1.68%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Northwest Biotherapeutics's Float Percentage Of Total Shares Outstanding is 95.74%.

Northwest Biotherapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Northwest Biotherapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northwest Biotherapeutics Institutional Ownership Chart

Northwest Biotherapeutics Historical Data

The historical data trend for Northwest Biotherapeutics can be seen below:

2022-11-30 2022-12-31 2023-01-31 2023-02-28 2023-03-31 2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31
Institutional Ownership 0.04 0.04 0.04 0.04 0.03 0.03 0.03 0.02 0.02 0.02
NWBO
11GF Score
Northwest Biotherapeutics Inc NWBO
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Northwest Biotherapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.02% mean?
Northwest Biotherapeutics (NWBO) has a Institutional Ownership of 0.02% as of Jul. 21, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Northwest Biotherapeutics and its competitors.
Is Northwest Biotherapeutics' Institutional Ownership too high?
Northwest Biotherapeutics' current Institutional Ownership is 0.02%. Overall, Northwest Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' Institutional Ownership compare to LCTX and VRXA?
Northwest Biotherapeutics' Institutional Ownership of 0.02% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Northwest Biotherapeutics and its competitors. Northwest Biotherapeutics's current Institutional Ownership is 0.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Northwest Biotherapeutics (NWBO) has a current Institutional Ownership of 0.02%. The current Institutional Ownership is 0.02%. Northwest Biotherapeutics' overall GF Score™ is 11/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Northwest Biotherapeutics (NWBO), the current Institutional Ownership is 0.02% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Northwest Biotherapeutics Business Description

Other Exchanges NBYB:Germany
Address 4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
11GF Score

Get the complete analysis for NWBO

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price